ArticleCancer medicine2024

Immunotherapy combined with antiangiogenic therapy as third- or further-line therapy for stage IV non-small cell lung cancer patients with ECOG performance status 2: A retrospective study.

Shuo Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.